Biopharma company GenSight Biologics S.A. (Euronext Paris:SIGHT) announced on Wednesday that after five years of follow-up, Leber Hereditary Optical Neuropathy (LHON) subjects treated with LUMEVOQ (GS010) continued to experience significantly improved vision as a result of a one-time injection of the gene therapy treatment.
The large long-term follow-up study for a rare disease treatment, named RESTORE, involved 62 subjects accepting the invitation to enrol and 55 completing the study. All subjects, who were affected by LHON caused by a mutated ND4 mitochondrial gene, were treated with an intravitreal injection of LUMEVOQ in one eye and with sham injection in the other.
The company said that when compared to the trend in vision observed among untreated patients, the findings are a significant divergence from the natural outcomes of LHON, a rare maternally inherited mitochondrial genetic disease. LHON is characterised by the degeneration of retinal ganglion cells that results in irreversible vision loss that can lead to legal blindness. The disease mainly affects adolescents and young adults.
GenSight Biologics is focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference